Nycomed

Nycomed

NycomedNycomed is a Takeda company since end of September 2011. Takeda is a research-based global company with its main focus on pharmaceuticals. The combined company has an active commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.

Takeda's traditional strengths in North America, Japan, and the rest of Asia, are now complemented by Nycomed's position in Europe and the high growth emerging markets. The combined company has a presence in more than 70 countries worldwide, and ranked 12th by global Rx sales, 14th in the BRIC countries and 18th in Europe. For more information visit www.nycomed.com.

Nycomed RSS Channel

Filters
List of articles in category Nycomed
Title Published Date
Takeda Appoints Jostein Davidsen Head of Emerging Markets 20 October 2011
Nycomed reports double-digit growth across emerging markets in second quarter 2011 17 August 2011
Nycomed continues to outperform in emerging markets in first quarter 2011 26 May 2011
Takeda to Acquire Nycomed - Transaction will Transform Takeda's Global Business 19 May 2011
Nycomed well positioned in emerging markets 02 March 2011
Nycomed Announces Agreement with Eurand for ZENPEP® in Russia-CIS 12 January 2011
Daxas® (Roflumilast) included as a new treatment option in latest international COPD guidelines 06 January 2011
Nycomed is keeping the pace in third quarter 2010 10 November 2010
Global market launch of Daxas® (Roflumilast) kicks off in Germany 01 September 2010
Nycomed's Daxas® (roflumilast) receives marketing authorisation in the European Union 07 July 2010
Nycomed's first quarter 2010 results confirm the direction 14 May 2010
Nycomed's novel anti-inflammatory therapy Daxas® (roflumilast) recommended for approval in the European Union 27 April 2010
Nycomed on track in 2009 with strong growth in Key Products 02 March 2010
Nycomed sustains commitment to Russia-CIS and invests in new pharmaceutical production plant 22 September 2009
Nycomed reports sustained momentum in second quarter 2009 20 August 2009
Nycomed to acquire local portfolio from Sanofi-Aventis and Zentiva 03 August 2009
Nycomed's Instanyl® is first intranasal fentanyl approved in Europe 27 July 2009
Nycomed receives Marketing Authorization for Pantoprazole 20mg OTC from European Commission 20 June 2009
Nycomed Reports a Solid Start to 2009 28 May 2009
Nycomed files European marketing authorisation application for Daxas® 11 May 2009